Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 102Breast Neoplasms 10Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 6Triple Negative Breast Neoplasms 5Castration-resistant Prostate Cancer 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Prostate Cancer Metastatic 2Prostate Adenocarcinoma 2Ovarian Neoplasms 2Neoplasms 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Metastatic Castration-Resistant Prostate Cancer 2Metastatic Castration Resistant Prostate Cancer 2Castration Resistant Metastatic Prostate Cancer 2Carcinoma, Hepatocellular 2Adenocarcinoma of the Prostate 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Thrombocytosis 1Stomach Neoplasms 1Solid Tumor 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Castration-resistant Prostate Cancer Patients with Oligometastases × enzalutamide × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡